The Absolute Effect / Evidence index
Locoregional / Embolisation-Eligible · Phase III global randomized open-label; N=760; embolisation-eligible HCC. STRIDE (durvalumab+tremelimumab) + lenvatinib + TACE; STRIDE+TACE; or TACE. PFS and OS assessed. · STRIDE+lenvatinib+TACE vs TACE: median PFS 13.0 vs 9.8 months
EMERALD-3
Clinical question: Does STRIDE plus lenvatinib added to TACE improve PFS over TACE alone in embolisation-eligible hepatocellular carcinoma?
STRIDE+lenvatinib+TACE vs TACE: median PFS 13.0 vs 9.8 months; HR 0.70 (95% CI 0.57–0.86; P=0.0007). Median OS 39.5 vs 34.7 months; HR 0.84 (95% CI 0.65–1.09; P=0.18). · Registry:
Design, population and treatment
Phase III global randomized open-label; N=760; embolisation-eligible HCC. STRIDE (durvalumab+tremelimumab) + lenvatinib + TACE; STRIDE+TACE; or TACE. PFS and OS assessed.
Key efficacy outcome
Grade-specific toxicity not reproduced in the retrieved abstract summary; consult primary paper tables.
Safety and absolute effect
Median PFS (months)
https://www.sciencedirect.com/science/article/pii/S1470204526002780
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.